MedMatrix Rx
Daily 340B Morning Briefing for Executives
Recent developments in the 340B program include a bipartisan bill proposing a two-year delay of the 340B rebate pilot, which would shift the model from requiring upfront discounts to implementing post-sale rebates starting January 1, 2027. This delay, introduced in response to concerns from stakeholders, aims to extend the current discount structure until December 31, 2028. Concurrently, the Health Resources and Services Administration (HRSA) has approved 10 drugmakers to participate in the revised rebate model. A report from the Department of Health and Human Services (HHS) has raised alarms regarding the impact of spread pricing on hospital profits and patient care. The American Hospital Association (AHA) has responded by filing a lawsuit to block the rebate pilot, citing financial strain on hospitals. These developments reflect ongoing tensions between drug manufacturers and healthcare providers regarding the sustainability and efficacy of the 340B program.
EXECUTIVE SUMMARY
01
New bill proposes two-year delay of 340B rebate pilot.
Bipartisan legislation introduced to delay HRSA’s 340B rebate model pilot, requiring upfront discounts from Jan. 1, 2027, to Dec. 31, 2028.
Bipartisan legislation introduced to delay HRSA’s 340B rebate model pilot, requiring upfront discounts from Jan. 1, 2027, to Dec. 31, 2028.
Source: Becker’s Hospital Review
02
HRSA approves 10 drugmakers for 340B rebate pilot.
HRSA approved 10 drugmakers for a revised 340B rebate model pilot, replacing upfront discounts with post-sale rebates starting Jan. 1, 2027.
HRSA approved 10 drugmakers for a revised 340B rebate model pilot, replacing upfront discounts with post-sale rebates starting Jan. 1, 2027.
Source: Becker’s Hospital Review
03
HHS report flags 340B spread pricing concerns.
An HHS report raised concerns about 340B program expansion, spread pricing, and its impact on hospital profits over patient care.
An HHS report raised concerns about 340B program expansion, spread pricing, and its impact on hospital profits over patient care.
Source: TechTarget
04
AHA sues over 340B rebate pilot plan.
The American Hospital Association filed a lawsuit to block the 340B rebate pilot, citing financial strain and increased costs for hospitals.
The American Hospital Association filed a lawsuit to block the 340B rebate pilot, citing financial strain and increased costs for hospitals.
Source: STAT News
05
CMS opens new portal for 340B data submissions.
CMS launched a Medicare Part D Claims Data 340B Repository for voluntary submissions, ahead of mandatory data submission starting Jan. 1, 2027.
CMS launched a Medicare Part D Claims Data 340B Repository for voluntary submissions, ahead of mandatory data submission starting Jan. 1, 2027.
Source: Becker’s Hospital Review
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The proposed delay of the 340B rebate pilot and the ongoing legal challenges present significant implications for covered entities, particularly hospitals. The extension of the current discount model allows these entities to maintain financial support while managing the complexities of drug pricing and reimbursement. However, the concerns raised in the HHS report regarding spread pricing could exacerbate existing financial pressures, impacting patient care and access to medications. As the AHA’s lawsuit progresses, the outcome may set precedents for how the 340B program is implemented and regulated, influencing the financial viability of hospitals that rely on these discounts to serve vulnerable populations.
Emerging risks.
- Hospitals face significant financial losses from CMS’ proposed 340B payment cuts, impacting service delivery.
- Legal challenges to 340B policies may disrupt program stability and hospital operations.
- The 340B rebate pilot could impose administrative burdens on hospitals, affecting cash flow.
- State laws mandating 340B discounts to contract pharmacies may lead to increased litigation from manufacturers.
Emerging opportunities.
- Hospitals can use the new CMS portal to streamline 340B data submissions.
- The delay in the 340B rebate pilot allows time to advocate for favorable legislative changes.
- Engagement in litigation provides a platform to influence 340B policy outcomes.
- Participation in the 340B rebate pilot provides a chance to shape future program models.
Key actions for providers.
- Monitor legislative developments related to the 340B rebate pilot delay.
- Prepare for mandatory 340B data submissions by familiarizing with the CMS portal.
- Engage with policymakers to advocate for hospital interests in 340B policy.
- Assess financial impact of CMS’ proposed 340B payment cuts and plan accordingly.
TOP STORIES
New bill proposes two-year delay of 340B rebate pilot.
Becker’s Hospital Review · October 13, 2026
- The bill requires upfront 340B discounts from Jan. 1, 2027, to Dec. 31, 2028.
- Federal funds would be barred from implementing the rebate pilot during this period.
- The pause aims to give Congress time to consider broader 340B reforms.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
HRSA approves 10 drugmakers for 340B rebate pilot.
Becker’s Hospital Review · October 2, 2026
- The pilot replaces upfront discounts with post-sale rebates for selected drugs.
- Approved manufacturers include AbbVie, Amgen, and AstraZeneca.
- The pilot is set to begin on January 1, 2027.
HHS report flags 340B spread pricing concerns.
TechTarget · October 12, 2026
- The report addressed program expansion and unintended incentives favoring hospital profits.
- Concerns include duplicate discounts and contract pharmacy use.
- The report suggests changes in Medicare reimbursement to address these issues.
340B PROGRAM DEVELOPMENTS
AHA sues over 340B rebate pilot plan.
STAT News · October 9, 2026
- The lawsuit challenges the 340B rebate pilot’s financial impact on hospitals.
- AHA argues the pilot would increase drug purchasing costs and strain cash flow.
- The lawsuit follows a previous successful challenge to a similar plan.
Drugmakers’ 340B rebate fight explained.
Becker’s Hospital Review · October 12, 2026
- J&J ceased its rebate plan after HRSA’s warning of illegality.
- Lilly filed a suit over its rebate model requiring upfront payments.
- Sanofi plans a credit model for 340B hospitals starting November 22.
340B rebate model: 2027 claims and payment rules.
HFMA · October 5, 2026
- The rebate model involves new claims requirements for hospitals.
- Participating manufacturers use the Beacon platform for claims submission.
- The model faces potential disruption from ongoing litigation and legislation.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| D. Me. | AMERICAN HOSPITAL ASSOCIATION v. KENNEDY — Motion to Intervene by AbbVie Inc., pharmacyclics LLC, bristol-myers squibb company, boehringer ingelheim pharmaceuticals, inc. Responses due by 11/4/2026. Case filed October 9, 2026. [source] | October 14, 2026 |
| M.D. Fla. | Florida Health Sciences Center, Inc. v. Eli Lilly and Company — Response to Motion re motion to Dismiss Plaintiff’s Complaint and As-Applied Challenge to the Constitutionality of Section 501.201 to 501.213, Fla. Stat. Case filed July 2, 2026. [source] | October 14, 2026 |
| S.D.N.Y. | Mount Sinai Hospital v. CVS Health Corporation — Protective ORDER.regarding procedures to be followed that shall govern the handling of confidential material. (.). Case filed May 18, 2026. [source] | October 13, 2026 |
| Bankr. D. Del. | Akorn Holding Company LLC — Motion to Approve Compromise under Rule 9019 Filed by George L. Miller. Hearing scheduled for 11/20/2026 at 10:00 am at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom 3, Wilmington, Delaware. Case filed February 23, 2023. [source] | October 9, 2026 |
| D.D.C. | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA v. KENNEDY JR. — Complaint against center for medicare and medicaid innovation, centers for medicare & medicaid services, robert F. kennedy jr., mehmet oz, abe sutton, united states department of health and human services. Case filed October 7, 2026. [source] | October 7, 2026 |
| D.N.H. | Mary Hitchcock Memorial Hospital v. Eli Lilly and Company — Surreply to Reply to 5 motion for Preliminary Injunction Def’s Surreply in Opposition to Plt’s Motion for Preliminary Injunction. Case filed July 27, 2026. [source] | October 6, 2026 |
| 8th Cir. | Astrazeneca Pharmaceuticals, LP v. Marty Jackley — Reply to response to petition for initial hearing en banc. Case filed August 11, 2026. [source] | September 25, 2026 |
| 8th Cir. | Pharm. Res. & Mfr. of America v. Marty Jackley — Motion to file a reply to response,. Case filed August 25, 2026. [source] | September 25, 2026 |
MANUFACTURER WATCH
| Manufacturer | Action | Date |
|---|---|---|
| Sanofi, AstraZeneca, Novo Nordisk | Won a federal appeals court ruling in a 340B distribution dispute. [source] | October 16, 2026 |
| AbbVie | Lost a legal challenge against Mississippi 340B law requiring discounts to contract pharmacies. [source] | September 12, 2025 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
I conducted a web search for recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, focusing on reactions, statements, op-eds, and advocacy positions from hospital and health-center groups, provider and patient advocates, drug manufacturers, PBMs, and policy commentators, including LinkedIn posts, Reddit discussions, and Substack/newsletter opinions.
AHA Supports 340B Rebate Model Delay Act (H.R. 10770)
American Hospital Association · October 15, 2026
- Main theme: AHA’s support for delaying the 340B Rebate Model Pilot Program
- Stakeholder sentiment: The American Hospital Association (AHA) supports the 340B Rebate Model Delay Act (H.R. 10770), which aims to pause the Department of Health and Human Services’ 340B Rebate Model Pilot Program, set to begin on January 1, 2027.
- Potential implications: Delaying the rebate model could maintain current 340B program operations and benefits for hospitals and patients.
- Credibility: The AHA is a reputable organization representing hospitals and healthcare networks.
AHA and Others File Lawsuit to Halt Costly 340B Rebate Program
American Hospital Association · October 9, 2026
- Main theme: AHA’s legal action against the expanded 340B rebate program
- Stakeholder sentiment: The AHA, along with the Maine Hospital Association and four safety-net hospitals, filed a lawsuit challenging changes by the Department of Health and Human Services to the 340B Drug Pricing Program that would expand the use of a proposed rebate model previously halted by the courts.
- Potential implications: The lawsuit aims to prevent the implementation of the expanded rebate program, which could impact hospital operations and patient care.
- Credibility: The AHA is a reputable organization representing hospitals and healthcare networks.
AHA Files Amicus Brief Supporting Hospital in Challenge to Lilly 340B Policy
American Hospital Association · October 2, 2026
- Main theme: AHA’s support for a hospital challenging Eli Lilly’s 340B claims data policy
- Stakeholder sentiment: The AHA, the New Hampshire Hospital Association, and 340B Health filed an amicus brief supporting Mary Hitchcock Memorial Hospital’s request for a preliminary injunction against Eli Lilly’s new 340B claims data policy.
- Potential implications: The amicus brief supports the hospital’s challenge, which could influence future 340B claims data policies.
- Credibility: The AHA is a reputable organization representing hospitals and healthcare networks.
WHAT TO WATCH NEXT
- HRSA’s next steps following the federal appeals court ruling favoring Sanofi, AstraZeneca, and Novo Nordisk. [source]
- Congressional action on the proposed delay of the 340B rebate pilot. [source]
- CMS’ response to hospitals’ feedback on the proposed 340B payment cuts. [source]
- Potential further litigation from the American Hospital Association regarding the 340B rebate pilot. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.